The faltering economy has reduced the spending capacity of the consumer to indulge in cosmetics. This results to lower profit for most cosmetic companies, save for Allergan—the renowned manufacturer/distributor of Botox.  

In the upcoming months of 2009, Allergan Botox will be getting competition from a rival medical manufacturer. Reloxin—a competitor of Allergan Botox—is now in the pending stages of approval of the Food and Drug Administration (FDA). But that’s the least of Allergan’s problems, because the company still has to worry about staying afloat amidst the economic crisis.

Experts anticipate a 10 percent decrease in Botox sales and breast-implant sales. However, Allergan has invested in many areas of the cosmetic industry—a move that secures its place in the market.

Allergan has invested in the eye care sales, which can curdle losses to make the company more stable. The company also celebrated the FDA-approval of a new product: Latisse. It’s a topical solution, which is used to grow eyelashes. Also, experts say that once prices and consumer demand have stabilized, there’s a big door for respectable profit.

Other cosmetic companies that are fairing relatively compared to others are: Avon, Estée Lauder, Medicis Pharmaceutical, and Bare Essentials.